Coherus Oncology, Inc.

CHRS Healthcare Biotechnology

In the quarter to June 2026, revenue grew 39.5%, EPS fell 105.1%, free cash flow fell 33.2% and total debt rose 1.03%, each against the same quarter a year earlier.

1.00 0.07 −6.54%
Market cap
$165.3M
P/E
0.0×
Fwd P/E
−1.4×
Dividend yield
—
F-score
6/9
Altman Z
−8.83
Beneish M
−3.44
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Piotroski F-Score
6 4 3 1 2 — — — 2 3
P/E ratio
0.97 5.11 0.00 0.00 0.00 9.39 14.07 — 0.00 0.00
Altman Z-Score
(8.83) (5.93) (3.67) (4.03) (0.95) 2.12 1.82 — (8.39) (0.14)
P/S ratio
3.94 5.99 1.15 3.13 3.69 2.61 3.52 — 211.43 6.17
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 8.45 47.30 — 0.00 0.00
Altman Z″-Score (non-manufacturers)
(20.15) (13.65) (9.10) (9.61) (3.25) 3.67 (1.34) — (20.17) (10.19)
P/Operating CF
(8.44) 5.53 (22.85) (6.61) (23.01) 37.47 70.86 — (16.96) (13.51)
Beneish M-Score
(3.44) (3.21) (1.39) (2.77) (4.41) (2.50) — — — 4.91
P/B ratio
2.73 0.00 0.00 0.00 12.32 4.42 11.93 — 16.62 60.64
Price to Tangible BV
11.26 0.00 0.00 0.00 12.79 4.47 12.35 — 18.81 74.32
EV/Sales
4.89 17.89 2.55 4.47 4.04 2.33 3.53 — 200.86 6.04
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 6.95 11.33 — 0.00 0.00
EV/Operating CF
(1.49) (23.09) (3.75) (3.92) (35.28) 7.18 44.36 — (2.41) (4.55)
EV/FCF
(1.48) (22.08) (3.73) (3.88) (34.10) 7.54 47.41 — (2.35) (4.43)
Quick Ratio
1.36 0.88 1.14 2.17 3.27 4.79 2.78 2.18 4.47 2.25
Current Ratio
1.47 1.21 1.43 2.75 3.64 5.27 2.98 2.54 5.12 2.86
Net Debt/EBITDA
0.76 (0.71) (1.78) (1.10) 0.03 (0.86) 0.01 (0.15) 0.11 0.22
Debt/Assets
14.34% 59.07% 75.19% 97.96% 60.10% 48.00% 43.62% 103.64% 62.49% 56.17%
Debt/Equity
0.61 (2.01) (2.45) (3.43) 4.18 1.44 1.70 (2.67) 3.33 5.18
Asset Turnover
0.12 0.05 0.46 0.36 0.43 0.76 1.40 0.00 0.01 0.97
Operating CF/Net income
(0.82) (0.72) 0.74 0.83 0.13 1.17 0.32 0.76 0.84 1.98
Capex/Depreciation
0.00 0.00 (0.08) (0.55) (0.37) (2.50) (0.56) (0.24) (1.35) (2.17)
Interest Coverage
(20.12) (18.60) (5.01) (7.91) (11.49) 7.39 6.12 (21.11) (24.30) (14.53)
ROE
(473.47%) (17.52%) 143.81% 1,470.09% (151.62%) 68.49% 269.68% 5,197.10% (954.80%) (2,049.69%)
ROA
47.54% 5.29% (42.85%) (50.29%) (37.75%) 21.15% 35.34% (159.75%) (139.65%) (65.16%)
ROIC
0.00% (1,795.44%) (78.30%) (113.10%) (185.69%) 67.92% 63.58% 0.00% (2,805.20%) 0.00%
Return on Tangible Assets
248.32% 46.60% (159.68%) (116.10%) (64.54%) 20.93% 38.41% (361.98%) (183.41%) (109.89%)
Average Days of Receivables
159.41 1,692.07 369.65 190.18 137.51 120.47 145.55 — 0.00 3.57
Research and Development Expense of Revenue
258.20% 348.00% 42.54% 94.46% 111.19% 30.00% 26.45% 0.00% 10,436.31% 133.84%
Selling, General and Administrative Expense of Revenue
238.56% 475.51% 74.64% 94.05% 51.97% 29.23% 38.49% 0.00% 4,582.46% 27.14%
Intangible Assets out of Total Assets
0.18 0.12 0.11 0.01 0.01 0.00 0.01 0.04 0.02 0.02
Share Based Compensation of Revenue
40.23% 105.35% 16.76% 24.04% 15.73% 8.02% 9.43% 0.00% 2,146.34% 14.42%
Graham Net Nets
0.06 (1.51) (1.17) (0.36) 0.02 0.17 0.03 — 0.03 0.00
Graham Number
4.14 0.00 10.90 12.24 0.00 12.80 6.59 — 0.00 0.00
Earnings Yield
102.82% 19.57% (81.85%) (44.18%) (24.19%) 10.64% 7.11% — (47.64%) (11.32%)
Free Cash Flow Yield
(83.84%) (13.53%) (59.47%) (36.81%) (3.22%) 11.84% 2.11% — (40.37%) (22.08%)
Revenue per Share
0.36 0.23 2.73 2.72 4.33 6.66 5.11 0.00 0.03 4.54
Operating CF per Share
(1.18) (0.18) (1.86) (3.11) (0.50) 2.16 0.41 (2.45) (3.77) (6.03)
Capex per Share
0.00 0.00 0.00 (0.03) (0.02) (0.10) (0.03) (0.01) (0.09) (0.16)
Free Cash Flow per Share
(1.18) (0.18) (1.86) (3.13) (0.51) 2.06 0.38 (2.46) (3.86) (6.18)
Cash per Share
1.47 1.10 1.25 2.47 5.53 7.58 2.55 1.11 2.39 2.98
Shareholders Equity per Share
0.52 (1.15) (2.05) (1.77) 1.30 3.93 1.51 (0.59) 0.57 0.46
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
0.52 (1.15) (2.05) (1.77) 1.30 3.93 1.51 (0.59) 0.57 0.46
Free Cash Flow
(138.51) (20.44) (175.17) (243.16) (38.72) 146.91 26.53 (160.05) (204.86) (259.06)
Working Capital
66.32 58.60 143.86 242.54 437.00 621.83 228.04 51.17 117.08 105.11
Capital Expenditures
— — (0.29) (2.04) (1.29) (7.23) (1.82) (0.79) (4.57) (6.51)
Net Current Asset Value
9.38 (238.94) (347.40) (237.03) 20.72 206.80 39.30 (53.62) 13.40 2.36
EV/EBIT
0.00 0.00 0.00 0.00 0.00 7.08 11.67 — 0.00 0.00
Capex to Sales
0.00 0.00 0.00 0.01 0.00 0.02 0.01 0.00 2.94 0.03
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 7.94 11.64 — 0.00 0.00
Other line items
Depreciation/Fixed assets
2.92 2.05 0.74 0.42 0.44 0.29 0.56 0.49 0.27 0.28
Cash ROIC
(51.27%) (7.89%) (44.05%) (46.29%) (4.19%) 11.98% 5.75% (116.91%) (79.06%) (105.90%)
Accounts Receivable Turnover
0.60 0.14 1.39 1.81 2.33 3.18 4.95 — 0.00 111.21
Accounts Payable Turnover
0.72 0.27 6.80 5.06 3.67 1.83 0.83 0.21 0.00 0.00
Inventory Turnover
3.74 0.26 3.14 1.83 1.41 1.39 2.98 0.03 — —
Average Days of Payables
261.98 1,190.15 80.85 60.03 102.41 147.30 555.37 1,725.60 0.00 0.00
Days of Inventory on Hand
83.81 175.95 143.72 202.03 238.57 428.63 209.60 187.18 — —
Average Receivables
70.38 191.43 185.24 116.49 140.03 149.52 71.93 — — 1.71
Average Payables
19.19 31.84 23.37 13.84 15.68 20.59 20.64 15.50 18.15 25.04
Average Inventory
3.69 33.41 50.70 38.22 40.94 27.02 5.73 129.33 — —
Average Assets
353.44 539.07 555.23 580.09 760.49 625.29 254.20 131.04 170.55 195.43
Average Common Equity
(35.49) (162.71) (165.42) (19.85) 189.35 193.09 33.31 (4.03) 24.94 6.21

Fold the line items

Columns are period end dates